$236 a share
Profit Margin (ttm): -9.19%
Operating Margin (ttm): -5.84%
Funny how when asked to present the thought process behind your statement, you draw a blank. Sorta what I expected though. Consistent with your senseless posts.
"You can't eat potential"
Please explain what $220 represents with Tesla?
I think that is fairly simple to understand. Yet more people appear to be ready to lose $220 than $1. Tesla has far greater hurdles to overcome imo than Cytori whch can be potentially used for a number of indications and has already demonstrated benefits in several of those. They have been approved in Europe as an orphan drug status for one. that is no simple task.
All I am stating that for me it is worth the risk. Others may and do disagree. I have done extensive due diligence and am buidling a fairly nice size position here.
the technology appears to be beneficial in and applicable for several different medical indications. A no brainer imo.
My confidence is not swayed by the daily trading swings or by the ignorant who post on message boards, like the poster I responded to. Set your goals and stand by them.
In fact, you probably can't afford to be in this stock and should find somewhere else to play it safe. Please don't read my posts, in the future. Thank you.
March 23, 2015 08:00 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present data from two preclinical studies describing safety and efficacy of ADRCs for treatment of thermal burn injuries at the Annual Meeting of the American Burn Association (ABA) in Chicago on April 21-24, 2015. This research, funded by the contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, was part of the package of data submitted to the US Government as part of the In-Process Review meeting that led to the execution of the current contract option valued at $14.1 million, and part of Cytori’s $106 million BARDA contract framework.
“These are encouraging data that support the advancement of Cytori Cell Therapy to accelerate wound healing in severe burn patients”
The first presentation will describe the use of Cytori Cell Therapy in combination with a widely used skin substitute in a full thickness burn injury model. Data to be presented show increased wound vascularity and maturation in wounds treated with Cytori Cell Therapy. The second presentation will describe a novel model of full thickness thermal burn injury with concomitant radiation exposure. Data to be presented demonstrate that delivery of Cytori Cell Therapy accelerates wound re-epithelialization in this context. These data will form the basis of an Investigational Device Exemption (IDE) package to be submitted to FDA for a proposed clinical trial using Cytori Cell Therapy in thermal burn injury.
Interest is growing.
You will understand what all the excitement is about.
So if you were one of those patients who have experienced great relief and improvement from a terrible condition due to the trial, would you still think it is all fluff?
Yes, that is true. Thank you for the rational view.
the share value sure does impede capital for advancement. Why can't these folks trade without trying to gain an advantage by using lies and deceit?